Combined neutrophil-to-lymphocyte ratio predicts progression-free survival in metastatic cervical cancer patients treated with immune checkpoint inhibitors.
This retrospective cohort analysis included 148 individuals diagnosed with metastatic or recurrent cervical cancer who received immune checkpoint inhibitors. The study was conducted at a single center, and follow-up duration was not reported. The primary exposure was the combined neutrophil-to-lymphocyte ratio (Combined.NLR), which incorporated pre-treatment and post-treatment measurements. Participants were categorized into groups based on median NLR values obtained before and after treatment.
The main outcome assessed was progression-free survival (PFS). Individuals in the poor Combined.NLR group exhibited a notably increased risk of disease progression compared to those in the good group. The hazard ratio for this increased risk was 1.355, with a 95% confidence interval of 1.006–1.824 and a p-value of 0.046. Additionally, a nomogram derived from the data demonstrated a concordance index of 0.70.
Safety data, including adverse events, serious adverse events, discontinuations, and tolerability, were not reported in the study. The analysis identified Combined.NLR as an independent prognostic factor for disease progression. However, the study design is observational, meaning the findings suggest association rather than causation. Limitations regarding the single-center setting and lack of reported follow-up duration should be considered when interpreting these results for broader clinical application.